Dorothee Hölzl1, Georg Hutarew1, Barbara Zellinger1, Hans U Schlicker1, Christoph Schwartz2, Peter A Winkler2, Karl Sotlar1, Theo F J Kraus3. 1. Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, 5020, Salzburg, Austria. 2. Department of Neurosurgery, University Hospital Salzburg, Paracelsus Medical University, Ignatz-Harrer-Str. 79, 5020, Salzburg, Austria. 3. Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, 5020, Salzburg, Austria. t.kraus@salk.at.
Abstract
PURPOSE: Gliomas are the most frequent primary brain tumors of adults. Despite intensive research, there are still no targeted therapies available. Here, we performed an integrated analysis of glioma and programmed cell death ligand 1 (PD-L1) in 90 samples including 58 glioma and 32 control brain tissues. METHODS: To identify PD-L1 expression in glioma, we performed immunohistochemical analysis of PD-L1 tumor proportion score (TPS) using the clinically valid PD-L1 22C3 antibody on 90 samples including controls and WHO grade I-IV gliomas. RESULTS: We found that PD-L1 is highly expressed in a subfraction of glioma cells. Analysis of PD-L1 levels in different glioma subtypes revealed a strong intertumoral variation of PD-L1 protein. Furthermore, we correlated PD-L1 expression with molecular glioma hallmarks such as MGMT-promoter methylation, IDH1/2 mutations, TERT promoter mutations and LOH1p/19q. CONCLUSION: In summary, we found that PD-L1 is highly expressed in a subfraction of glioma, indicating PD-L1 as a potential new marker in glioma assessment opening up novel therapeutic approaches.
PURPOSE:Gliomas are the most frequent primary brain tumors of adults. Despite intensive research, there are still no targeted therapies available. Here, we performed an integrated analysis of glioma and programmed cell death ligand 1 (PD-L1) in 90 samples including 58 glioma and 32 control brain tissues. METHODS: To identify PD-L1 expression in glioma, we performed immunohistochemical analysis of PD-L1 tumor proportion score (TPS) using the clinically valid PD-L1 22C3 antibody on 90 samples including controls and WHO grade I-IV gliomas. RESULTS: We found that PD-L1 is highly expressed in a subfraction of glioma cells. Analysis of PD-L1 levels in different glioma subtypes revealed a strong intertumoral variation of PD-L1 protein. Furthermore, we correlated PD-L1 expression with molecular glioma hallmarks such as MGMT-promoter methylation, IDH1/2 mutations, TERT promoter mutations and LOH1p/19q. CONCLUSION: In summary, we found that PD-L1 is highly expressed in a subfraction of glioma, indicating PD-L1 as a potential new marker in glioma assessment opening up novel therapeutic approaches.
Authors: Monika E Hegi; Robert-Charles Janzer; Wanyu L Lambiv; Thierry Gorlia; Mathilde C M Kouwenhoven; Christian Hartmann; Andreas von Deimling; Danielle Martinet; Nathalie Besuchet Schmutz; Annie-Claire Diserens; Marie-France Hamou; Pierre Bady; Michael Weller; Martin J van den Bent; Warren P Mason; René-Olivier Mirimanoff; Roger Stupp; Karima Mokhtari; Pieter Wesseling Journal: Acta Neuropathol Date: 2012-01-15 Impact factor: 17.088
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert Journal: J Clin Oncol Date: 2008-09-01 Impact factor: 44.544
Authors: Anna Sophie Berghoff; Barbara Kiesel; Georg Widhalm; Dorothee Wilhelm; Orsolya Rajky; Sebastian Kurscheid; Philip Kresl; Adelheid Wöhrer; Christine Marosi; Monika E Hegi; Matthias Preusser Journal: Neuro Oncol Date: 2017-10-19 Impact factor: 13.029
Authors: Luís Felipe Campesato; Romualdo Barroso-Sousa; Leandro Jimenez; Bruna R Correa; Jorge Sabbaga; Paulo M Hoff; Luiz F L Reis; Pedro Alexandre F Galante; Anamaria A Camargo Journal: Oncotarget Date: 2015-10-27
Authors: Theo F J Kraus; Christoph Schwartz; Lukas Machegger; Barbara Zellinger; Dorothee Hölzl; Hans U Schlicker; Johannes Pöppe; Barbara Ladisich; Mathias Spendel; Michael Kral; Karl Sotlar Journal: Brain Tumor Pathol Date: 2022-01-11 Impact factor: 3.298
Authors: Dorothee Hölzl; Georg Hutarew; Barbara Zellinger; Beate Alinger-Scharinger; Hans U Schlicker; Christoph Schwartz; Karl Sotlar; Theo F J Kraus Journal: Biomedicines Date: 2022-03-29